Safety and Antiviral Activity of Assembly Biosciences' First and Second Generation Core Inhibitor Candidates In the Treatment of Chronic Hepatitis B to be Featured in a Late Breaking Session at AASLD

Stock Information for Assembly Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Assembly Biosciences Inc.

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
Assembly Biosciences Announces Effective Date of Reverse Stock Split
Assembly Biosciences Provides Anticipated Development Milestones for 2024
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®
Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.